Home›Articles›How an accelerated approval widened into first line lung cancer treatmentArticleHow an accelerated approval widened into first line lung cancer treatmentArticlesConnectionsSourcesComments (0)Reader Challenges (0)ConnectionsArticle OnBrigatinib, Drugs and Medicinal Substances Well-attested SourcesBrigatinib (Wikipedia)Regulatory approval section, 2017 and 2020 approval sentencesQuote, Regulatory approval section, 2017 and 2020 approval sentencesOn 28 April 2017, it was granted an accelerated approval from the U.S. Food and Drug Administration (FDA) for metastatic non-small cell lung cancer (NSCLC); as a 2nd-line therapy for ALK-positive NSCLC. In 2020, it was approved as first-line treatment for ALK-positive metastatic NSCLC patients.View the SourceMedicine Atlas Original Articlestier 1Comments (0)No comments yet. Be the first to share a thought.Sign in to join the discussion.Reader Challenges (0)No disputes yet. Spotted an error or a better source? Open the first one.Sign in to dispute this or suggest a correction.